To determine the epigenetic regulatory mechanism of cancer stem cells by cell surface molecules.

通过细胞表面分子确定癌症干细胞的表观遗传调控机制。

• 批准号: 22650223
• 负责人: MORIMOTO Chikao
• 金额: $ 2.12万
• 依托单位: The University of Tokyo
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Challenging Exploratory Research
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22650223/
• 关键词: がん幹細胞; エピジェネティックス; B-ALL; 悪性中皮腫; CD9; CD24; CD26; USP22; 癌幹細胞; シグナル伝達; ノックダウン; RNAi; ヒストン脱ユビキチン酵素; がん; エピジェネティック; 表面抗原マーカー; CD34

In the current study, we performed more detailed analysis of CD9 function for the cancer stem cell properties of B-ALL. In patient samples, CD9 was expressed in the most cases of B-ALL cells with significant correlation of CD34-expression. Knockdown of CD9 remarkably reduced the leukemogenic potential and affected the expression and tyrosine phosphorylation of Src family protein and reduced the expression of histone-deubiquitinase USP22. In malignant mesothelioma our results showed that CD24 and CD26 differentially regulated the cancer stem cell potentials of MM and also CD26 expression closely correlated with expression of USP22. These results suggest that CD24, CD9 and CD26 could be the promising target for CSC-oriented therapy.

在当前的研究中，我们对B-All的癌症干细胞特性进行了更详细的CD9功能分析。在患者样品中，CD9在大多数B-All细胞中表达，CD34表达显着相关。 CD9的敲低显着降低了白血病潜力，并影响了SRC家族蛋白的表达和酪氨酸磷酸化，并降低了组蛋白 - 非素酶USP22的表达。在恶性间皮瘤中，我们的结果表明，CD24和CD26差异调节了MM的癌细胞干细胞电位，并且CD26表达与USP22的表达密切相关。这些结果表明，CD24，CD9和CD26可能是面向CSC的治疗的有希望的靶标。

项目成果

Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells

• DOI: 10.1016/j.bbrc.2012.02.054
• 发表时间: 2012-03-16
• 期刊: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
• 影响因子: 3.1
• 作者: Yamazaki, Hiroto;Naito, Motohiko;Morimoto, Chikao
• 通讯作者: Morimoto, Chikao

The role of CD26 in T-cell biology and T-cell malignancies. T-Cell Malignancies : Recent Developments and Novel Therapeutic Approaches

CD26 在 T 细胞生物学和 T 细胞恶性肿瘤中的作用。

• 作者: Havre PA;Dang LH;Abe M;Urasaki Y;Ohnuma K;Morimoto C;Dang NH
• 通讯作者: Dang NH

Stem cell property for T-cell malignancy. T-Cell Malignancies : Recent Developments and Novel Therapeutic Approaches

T 细胞恶性肿瘤的干细胞特性。

• 发表时间: 2010
• 作者: Ohnuma K;Hosono O;Dang NH;Morimoto C;Yamazaki H and Morimoto C
• 通讯作者: Yamazaki H and Morimoto C

Dipeptidyl peptidase in autoimmune pathophysiology.

• DOI: 10.1016/b978-0-12-385855-9.00003-5
• 发表时间: 2011
• 期刊: Advances in clinical chemistry
• 作者: K. Ohnuma;O. Hosono;N. Dang;C. Morimoto

T-Cell Malignancies : Recent Developmentsand Novel Therapeutic Approaches.

T 细胞恶性肿瘤：最新进展和新颖的治疗方法。

• 发表时间: 2010
• 作者: Yamazaki H;Morimoto C.
• 通讯作者: Morimoto C.